Amgen Inc.

Bristol-myers Squibb Compnay

Kiniksa Pharmaceuticals, Ltd.

Amgen K-a, Inc.

Kirin-amgen, Inc.

Ai Ching Lim

Chadwick Terence King

Ian Nevin Foltz

Yan Chen

Michael Wittekind

Martin C Wright

Jochem Gokemeijer

Alan S Harris

Lin Sun

Elena Getmanova

Randal Robert Ketchem

Christopher Mehlin

Joel E Tocker

Zhulun Wang

Nels Eric Pederson

Dirk E Smith

Xiaoshan Min

Sabine Schadow Escobar

Rutilio Clark

Michael R Comeau

Donghui Shi

Heather A Arnett

Saravanakumar Narayanan

Paul H Weinreb

James F Smothers

Jacques J Peschon

Marc A Gavin

David Fitzpatrick

Li Erran Li

Gunasekaran Kannan

Neeraj Jagdish Agrawal

Dong Xia

Kathy Manchulenko

Laura Sekirov

Dina N Alcorn

Eric Alan Butz

Christy Ann Thomson

Kelly Ann Berry

Cyr Clovis Chua De Imus

Li Li

Randal Robert Ketchum

Marc Alain Gavin

The invention provides anti-oncostatin M receptor-β (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.

Oncostatin M receptor antigen binding proteins

Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

Interleukin-2 muteins for the expansion of T-regulatory cells

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

ST2 antigen binding proteins

The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.

IL-17 receptor A antigen binding proteins

IL-17 Receptor A antigen binding proteins

Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

Libraries of modified fibronectin type III tenth domain-containing polypeptides

The invention provides anti-oncostatin M receptor-&#x3b2; (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.

Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.

The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.

Methods and compositions relating to anti-IL-21 receptor antibodies

Inhibitors of type 2 vascular endothelial growth factor receptors

Growing community of inventors

Mercer Island, WA, United States of America

Ai Ching Lim